RAF1 and cancer: Concerning the mechanism, these inhibitors demonstrate a stronger affinity for both BRAF homodimers and BRAF-CRAF heterodimers, yet they are less effective against CRAF, potentially suggesting reduced impact on KRAS-driven cancers [253].